Maxor National Pharmacy Services LLC this week announced that an agreement has been reached for its acquisition of Pharmaceutical Specialties Inc. (PSI). Read More »

Pfizer Inc. announced last week that its study to assess the safety, efficiency and immunogenicity of PF-06438179 called REFLECTIONS B537-02 has met its primary endpoint. Read More »

The Journal of Community and Supportive Oncology recently published a study that presented two key research findings dealing with treatment options for breast cancer. Read More »

Pfizer Inc. has announced that it has reached an agreement with AstraZeneca for the acquisition of the development and commercialization rights to its late-stage small molecule anti-infectives business. Read More »

Therapy combines Vigil engineered autologous tumor cells with durvalumab. Read More »

MRG anticipates improvements in customer and patient billing process, regulatory compliance and claims management. Read More »

Pfizer Inc. has announced that analysis of data from three studies involving VYNDAQEL have been published.  Read More »

Abbott has introduced its line of next-generation systems, call Alinity. Read More »

Bamboo research is focused on gene therapy for neuromuscular and central nervous system conditions. Read More »

Pfizer Inc. recently announced that its third Phase III study of XELJANZ (tofacitinib citrate), Oral Clinical Trials for tofacitinib in ulcerative colitis (OCTAVE) Sustain, has turned in positive result Read More »

Pfizer Inc. recently published the findings from two pivotal Phase III studies of crisaborole topical ointment 2 percent, formerly known as AN2728.  Read More »

Cancer vaccine WO-12 to be developed by Pfizer and Western Oncolytics. Read More »

Arizona Oncology is championing SpaceOar hydrogel, a new tool that has proven to protect patients with prostate cancer from the adverse effects of radiation therapy.  Read More »

Arizona Oncology recently broke ground during a ceremony celebrating its new cancer treatment center in East Valley. Read More »

Spark Therapeutics and Pfizer Inc. recently announced that SPK-9001 has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA).  Read More »

The World Health Organization (WHO) this week prequalified the four-dose, multi-dose vial (MDV) for Pfizer Inc.’s Prevenar 13. Read More »

Virginia Cancer Specialists (VCA) has enrolled its first patient in its upcoming advanced lung cancer clinical trial, making it the first center in the world to do so. Read More »

Pfizer announces positive results from year-long S-TRAC trial of SUTENT. Read More »

McKesson recently announced that it has acquired HealthQX, bolstering its portfolio by adding the value-based payment technology, ClarityQX. Read More »

FDA approves expanded age range for the pneumonia vaccine. Read More »